8-K: SELLAS Extends NYC Office Sublease to 2027

SELLAS Life Sciences Group, Inc. announced the extension of its New York City office sublease for an additional year, maintaining current annual rent.

Summary

• SELLAS Life Sciences Group, Inc. entered into a Letter Agreement with Times Square Tower Associates LLC on October 1, 2025.
• The agreement extends the expiration date of the existing sublease for its premises at 7 Times Square, New York, New York.
• The sublease expiration date has been extended from September 30, 2026, to September 30, 2027.
• The annual rent for the subleased premises remains unchanged under the terms of the extension.

Sentiment

Score: 6

Explanation: A routine operational extension of a key office lease with no rent increase is a stable, slightly positive development, but not transformative for the company's overall financial or strategic position.

Positives

• Secures office space for an additional year, providing operational stability.
• Annual rent remains unchanged, avoiding an increase in occupancy costs for the extended period.

Risks

• The company is obligated to indemnify the Sublandlord against any claims from brokers, finders, or like agents (other than CBRE, Inc.) arising from dealings claimed to have occurred between the company and the claimant in connection with this letter agreement.

Future Outlook

The company has secured its New York City office space until at least September 30, 2027, providing continuity for its operations at the current location.

Management Comments

• John T. Burns, Senior Vice President and Chief Financial Officer, signed the Letter Agreement on behalf of SELLAS Life Sciences Group, Inc.

Industry Context

This operational update reflects routine corporate real estate management. In the current economic climate, securing an office lease extension without an increase in annual rent can be viewed as a favorable outcome, especially as many companies re-evaluate their physical office footprints and associated costs.

Comparison to Industry Standards

• NA This is a specific, routine real estate transaction for a single company's office space. Direct comparable lease terms for other companies are not disclosed in this filing.

Stakeholder Impact

• Shareholders: Provides stability in operational costs and ensures continued physical presence in a key financial hub.
• Employees: Confirms continued stable office location in New York City for the foreseeable future.

Next Steps

• Continue operations at the New York office location until at least September 30, 2027.

Key Dates

Keywords

SELLAS Life Sciences, office lease, real estate, sublease extension, corporate operations, New York City office